AZM 475271Alternative Names: AZM-475271; M475271
Latest Information Update: 17 Aug 2015
At a glance
- Originator AstraZeneca
- Class Antineoplastics
- Mechanism of Action Src-Family kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haematological malignancies; Solid tumours
Most Recent Events
- 29 Oct 2008 Phase-I clinical trials in Solid tumours in USA (PO)
- 29 Oct 2008 Phase-II clinical trials in Haematological malignancies in USA (PO)